Superworth

Align Technology revenue ALGN

Sales by quarter and over the last twelve months, from 2009.

Last 12 months, to Jun 30, 2026
$4.1B
Latest quarter, Q2 FY26
$1.1B
+4% on a year earlier
Fiscal year 2025
$4B
+1% on the year before

Align Technology's revenue was $4.1B over the twelve months to Jun 30, 2026, up 4% on a year earlier.

In its latest quarter, Q2 FY26, it was $1.1B, up 4% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 10% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$4B+1%
FY2024$4B+4%
FY2023$3.9B+3%
FY2022$3.7B−6%
FY2021$4B+60%
FY2020$2.5B+3%
FY2019$2.4B+22%
FY2018$2B+33%
FY2017$1.5B+36%
FY2016$1.1B+28%
FY2015$845.5M+11%
FY2014$761.7M+15%
FY2013$660.2M+18%
FY2012$560M+17%
FY2011$479.7M+24%

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$1.1B+4%$4.1B
Q1 FY26$1B+6%$4.1B
Q4 FY25$1B+5%$4B
Q3 FY25$995.7M+2%$4B
Q2 FY25$1B−2%$4B
Q1 FY25$979.3M−2%$4B
Q4 FY24$995.2M+4%$4B
Q3 FY24$977.9M+2%$4B
Q2 FY24$1B+3%$3.9B
Q1 FY24$997.4M+6%$3.9B
Q4 FY23$956.7M+6%$3.9B
Q3 FY23$960.2M+8%$3.8B

Against its peers

Companies in Medical - Instruments & Supplies nearest Align Technology's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ALGNAlign Technology$4.1B+4% a year
GMEDGlobus Medical$3.1B+20% a year
COOCooper Companies$4.2B+5% a year
PODDInsulet$3.1B+29% a year
PENPenumbra$1.5B+18% a year
SOLVSolventum$8.3B−1% a year
MSAMSA Safety$1.9B+6% a year
MMSIMerit Medical Systems$1.6B+10% a year
HAEHaemonetics$1.4B+0% a year
VNTVontier$3.1B+1% a year
BMIBadger Meter$881M−2% a year
Peer median$2.5B

Where Align Technology ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Align Technology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.